Screening and treatment of latent tuberculosis infection among HIV-infected patients in resource-rich settings

References

• Houben RM, Crampin AC, Ndhlovu R, et al. Human immunodeficiency virus associated tuberculosis more often due to recent infection than reactivation of latent infection. Int J Tuberc Lung Dis. 2011;15:24–31.
   PubMed Web of Science ®Google Scholar
• Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009–1021.
   PubMed Web of Science ®Google Scholar
• Global Tuberculosis Report 2015. World Health Organization. [cited 2015 Nov 5] Available from: http://www.who.int/tb/publications/global_report/en/
   Google Scholar
• Global TB Facts 2015. World Health Organization. [cited 2015 Nov 5]. Available from: http://www.who.int/tb/Global_TB_Facts.pdf?ua=1
   Google Scholar
• Recommendation on 36 Months Isoniazid Preventive Therapy to Adults and Adolescents Living with HIV in Resource-Constrained and High TB- and HIV-Prevalence Settings: 2015 Update. World Health Organization. [cited 2015 Nov 7]. Available from: http://www.who.int/tb/publications/2015_ipt_update/en/
   Google Scholar
• Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:1588–1598.
   PubMed Web of Science ®Google Scholar
• Monge S, Diez M, Pulido F, et al. Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. Int J Tuberc Lung Dis. 2014;18:700–708.
   PubMed Web of Science ®Google Scholar
• Karo B, Haas W, Kollan C, et al. Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors. BMC Infect Dis. 2014;14:148.
   PubMed Web of Science ®Google Scholar
• Luigia E, Matthias S, Rainer W, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis. 2007;44:94–102.
   PubMed Web of Science ®Google Scholar
• Golub JE, Cohn S, Saraceni V, et al. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis. 2015;60:639–645.
   PubMed Web of Science ®Google Scholar
• 2015 Progress reports submitted by countries. The Joint United Nations Programmes on HIV/AIDS. [cited 2015 Oct 15]. Available from: http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries
   Google Scholar
• Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. World Health Organization. [cited 2015 Nov 1] Available from: http://www.who.int/hiv/pub/arv/advice/en/
   Google Scholar
• Tuberculosis countries profiles. World Health Organization. [cited 2015 Oct 15]. Available from: http://www.who.int/tb/publications/2015_ipt_update/en/
   Google Scholar
• The World Bank. [cited 2015 Oct 15]. Available from: http://data.worldbank.org/country
   Google Scholar
• De Vries G, Aldridge RW, Cayla JA, et al. Epidemiology of tuberculosis in big cities of the European Union and European Economic Area countries. Euro Surveill. 2014;19:pii: 20726.
   Google Scholar
• Framework towards tuberculosis elimination in low-incidence countries. World Health Organization. [cited 2015 Oct 15]. Available from: http://www.who.int/tb/publications/elimination_framework/en/
   Google Scholar
• Cheng MP, Jirji A, Roth DZ, et al. Tuberculosis in HIV-infected persons in British Columbia during the HAART era. Can J Public Health. 2014;105:e258e262.
   Google Scholar
• Gupta RK, Rice B, Brown AE, et al. Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland. Lancet HIV. 2015;2:e243–e251.
   PubMed Web of Science ®Google Scholar
• Luey C, Milne D, Briggs S, et al. HIV-associated tuberculosis in Auckland. N Z Med J. 2015;128:36–43.
   PubMedGoogle Scholar
• Zenner D, Abubakar I, Conti S, et al. Impact of TB on the survival of people living with HIV infection in England, Wales and Northern Ireland. Thorax. 2015;70:566–573.
   PubMed Web of Science ®Google Scholar
• Monge S, Diez M, Pulido F, et al. Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. Int J Tuberc Lung Dis. 2014;18:700–708.
   PubMed Web of Science ®Google Scholar
• Karo C, Haas W, Kollan C, et al. Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors. BMC Infect Dis. 2014;14:148.
   PubMed Web of Science ®Google Scholar
• Batista JD, De Albuquerque Mde F, Maruza M, et al. Incidence and risk factors for tuberculosis in people living with HIV: cohort from HIV referral health centers in Recife, Brazil. PLoS One. 2013;8:e63916.
   PubMedGoogle Scholar
• Trajman A, Steffen RE, Menzies D. Interferon-gamma release assays versus tuberculin skin testing for the diagnosis of latent tuberculosis infection: an overview of the evidence. Pulm Med. 2013;2013:601737.
   PubMedGoogle Scholar
• Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn. 2006;6:413–422.
   PubMed Web of Science ®Google Scholar
• Huebner RE, Villarino ME, Snider DE Jr. Tuberculin skin testing and the HIV epidemic. JAMA. 1992;267:409–410.
   PubMed Web of Science ®Google Scholar
• Elzi L, Steffen I, Furrer H, et al. Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection. BMC Infect Dis. 2011;11:319–327.
   PubMed Web of Science ®Google Scholar
• Metcalfe JZ, Everett CK, Steingart KR, et al. Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis. 2011;204(Suppl 4):S1120–S1129.
   PubMedGoogle Scholar
• Recommendations on the management of HIV and TB coinfection. Centre for Health Protection, Department of Health, Hong Kong SAR. [cited 2015 Nov 19]. Available from: http://www.chp.gov.hk/files/pdf/recommendations_on_the_management_of_human_immunodeficiency_virus_and_tuberculosis_coinfection_march_2015.pdf
   Google Scholar
• Guidelines on the management of latent TB infection. World Health Organization. [cited 2015 Nov 2]. Available from: http://www.who.int/tb/publications/latent-tuberculosis-infection/en/
   Google Scholar
• EACS Treatment Guideline 8.0. European AIDS Clinical Society. [cited 2015 Nov 19]. Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
   Google Scholar
• Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1–207.
   PubMedGoogle Scholar
• Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155–2166.
   PubMed Web of Science ®Google Scholar
• Jones S, De Gijsel D, Wallach FR, et al. Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals. Int J Tuberc Lung Dis. 2007;11:1190–1195.
   PubMed Web of Science ®Google Scholar
• Lee LM, Lobato MN, Buskin SE, et al. Low adherence to guidelines for preventing TB among persons with newly diagnosed HIV infection, United States. Int J Tuberc Lung Dis. 2006;10:209–214.
   PubMed Web of Science ®Google Scholar
• Brassard P, Hottes TS, Lalonde RG, et al. Tuberculosis screening and active tuberculosis among HIV-infected persons in a Canadian tertiary centre. Can J Infect Dis Med Microbiol. 2009;20:51–57.
   PubMed Web of Science ®Google Scholar
• Sester M, Van Leth F, Bruchfeld J, et al. Risk assessment of tuberculosis in immunocomprimised patients. A TBNET study. Am J Respir Crit Care Med. 2014;190:1168–1176.
   PubMed Web of Science ®Google Scholar
• Sañé Schepisi M, Parracino MP, Mammone A, et al. Immune status and serial Quantiferon-TB Gold In-Tube screening for latent Mycobacterium tuberculosis infection among HIV-Infected persons in a country with a low Tuberculosis incidence. J Infect Dis. 2015;211:1852–1853.
   PubMed Web of Science ®Google Scholar
• Bua A, Molicotti P, Ruggeri M, et al. Interferon-γ release assay in people infected with immunodeficiency virus. Clin Microbiol Infect. 2011;17:402–404.
   PubMed Web of Science ®Google Scholar
• Wolf T, Goetsch U, Oremek G, et al. Tuberculosis skin test, but not interferon-γ-releasing assays is affected by BCG vaccination in HIV patients. J Infect. 2013;66:376–380.
   PubMed Web of Science ®Google Scholar
• Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis. 2007;44:94–102.
   PubMed Web of Science ®Google Scholar
• Doyle JS, Bissessor M, Denholm JT, et al. Latent Tuberculosis screening using interferon-gamma release assays in an Australian HIV-infected cohort: is routine testing worthwhile? J Acquir Immune Defic Syndr. 2014;66:48–54.
   PubMed Web of Science ®Google Scholar
• Brock I, Ruhwald M, Lundgren B, et al. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res. 2006;7:56.
   PubMed Web of Science ®Google Scholar
• Cheallaigh CN, Fitzgerald I, Grace J, et al. Interferon gamma release assays for the diagnosis of latent TB infection in HIV-infected individuals in a low TB burden country. PLoS One. 2013;8:e53330.
   PubMedGoogle Scholar
• Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis. 2009;48:954–962.
   PubMed Web of Science ®Google Scholar
• Pullar ND, Steinum H, Tonby K, et al. Low prevalence of positive interferon-gamma tests in HIV-positive long-term immigrants in Norway. Int J Tuberc Lung Dis. 2014;18:180–187.
   PubMed Web of Science ®Google Scholar
• Bourgarit A, Baron G, Breton G, et al. Latent tuberculosis infection screening and 2-year outcome in antiretroviral-naive HIV-infected patients in a low-prevalence country. Ann Am Thorac Soc. 2015;12:1138–1145.
   PubMedGoogle Scholar
• Sultan B, Benn P, Mahungu T, et al. Comparison of two interferon-gamma release assays (QuantiFERON-TB Gold In-Tube and T-SPOT.TB) in testing for latent tuberculosis infection among HIV-infected adults. Int J STD AIDS. 2013;24:775–779.
   PubMed Web of Science ®Google Scholar
• Kall MM, Coyne KM, Garrett NJ, et al. Latent and subclinical tuberculosis in HIV-infected patients: a cross-sectional study. BMC Infect Dis. 2012;12:107.
   PubMedGoogle Scholar
• Pollock KM, Tam H, Grass L, et al. Comparison of screening strategies to improve the diagnosis of latent tuberculosis infection in the HIV-positive population: a cohort study. BMJ Open. 2012;2:e000762.
   Google Scholar
• Martínez-Pino I, Sambeat MA, Lacalle-Remigio JR, et al. Incidence of tuberculosis in HIV-infected patients in Spain: the impact of treatment for LTBI. Int J Tuberc Lung Dis. 2013;17:1545–1551.
   PubMed Web of Science ®Google Scholar
• Ramos JM, Robledano C, Masiá M, et al. Contribution of interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: a comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test. BMC Infect Dis. 2012;12:169.
   PubMed Web of Science ®Google Scholar
• Diaz A, Diez M, Bleda MJ, et al. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain. BMC Infect Dis. 2010;10:267.
   PubMedGoogle Scholar
• Santin M, Casas S, Saumoy M, et al. Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-γ release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagn Microbiol Infect Dis. 2011;69:59–65.
   PubMed Web of Science ®Google Scholar
• Diaz A, Diez M, Bleda MJ, et al. Prevalence of M. tuberculosis infection and tuberculosis disease among HIV-infected people in Spain. Int J Tuberc Lung Dis. 2007;11:1196–1202.
   PubMed Web of Science ®Google Scholar
• Balcells ME, Pérez CM, Chanqueo L, et al. A comparative study of two different methods for the detection of latent tuberculosis in HIV-positive individuals in Chile. Int J Infect Dis. 2008;12:645–652.
   PubMed Web of Science ®Google Scholar
• Garcia-Elorriaga G, Martinez-Velazquez M, Gaona-Flores V, et al. Interferonγin patients with HIV/AIDS and suspicion or latent tuberculosis infection. Asian Pac J Trop Med. 2013;6:135–138.
   PubMed Web of Science ®Google Scholar
• Jam S, Sabzvari D, SeyedAlinaghi S, et al. Frequency of Mycobacterium tuberculosis infection among Iranian patients with HIV/AIDS by PPD test. Acta Med Iran. 2010;48:67–71.
   PubMedGoogle Scholar
• Mardani M, Tabarsi P, Mohammadtaheri Z, et al. Performance of QuantiFERON-TB Gold test compared to tuberculin skin test in detecting latent tuberculosis infection in HIV- positive individuals in Iran. Ann Thorac Med. 2010;5:43–46.
   PubMed Web of Science ®Google Scholar
• Baboolal S, Ramoutar D, Akpaka PE. Comparison of the QuantiFERON®-TB Gold assay and tuberculin skin test to detect latent tuberculosis infection among target groups in Trinidad & Tobago. Rev Panam Salud Publica. 2010;28:36–42.
   PubMed Web of Science ®Google Scholar
• Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441–1448.
   PubMed Web of Science ®Google Scholar
• Souza JM, Evangelista Mdo S, Trajman A. Added value of QuantiFERON TB-gold in-tube for detecting latent tuberculosis infection among persons living with HIV/AIDS. Biomed Res Int. 2014;2014:294963.
   PubMedGoogle Scholar
• Moura LC, Ximenes RA, Ramos HL, et al. An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS.BMC. Public Health. 2011;11:687.
   PubMedGoogle Scholar
• Gutierrez EB, Gomes V, Picone C, et al. Active tuberculosis and Mycobacterium tuberculosis latent infection in patients with HIV/AIDS. HIV Med. 2009;10:564–572.
   PubMed Web of Science ®Google Scholar
• Lin WC, Lin HH, Lee SS, et al. Prevalence of latent tuberculosis infection in persons with and without human immunodeficiency virus infection using two interferon-gamma release assays and tuberculin skin test in a low human immunodeficiency virus prevalence, intermediate tuberculosis-burden country. J Microbiol Immunol Infect. 2014;pii: S1684–1182(14)00179-0.
   Google Scholar
• Yang C-H, Chan P-C, Liao S-T, et al. Strategy to better select HIV-infected individuals for latent TB treatment in BCG-vaccinated population. PLoS One. 2013;8:e73069.
   PubMedGoogle Scholar
• Zhang LF, Liu XQ, Zuo LY, et al. Longitudinal observation of an interferon gamma-released assay (T-SPOT.TB) for Mycobacterium tuberculosis infection in AIDS patients on highly active antiretroviral therapy. Chin Med J. 2011;123:1117–1121.
   Web of Science ®Google Scholar
• Lin AW, Chan KC, Chan WK, et al. Tuberculin sensitivity testing and treatment of latent tuberculosis remains effective for tuberculosis control in human immunodeficiency virus-infected patients in Hong Kong. Hong Kong Med J. 2013;19:386–392.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Kim SI, Kim YR, et al. Predictive value of interferon-γ ELISPOT assay in HIV 1-infected patients in an intermediate tuberculosis-endemic area. AIDS Res Hum Retroviruses. 2012;28:1038–1043.
   PubMedGoogle Scholar
• Khawcharoenporn T, Apisarnthanarak A, Manosuthi W, et al. Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV-infected Thai patients. Int J Tuberc Lung Dis. 2012;16:336–341.
   PubMed Web of Science ®Google Scholar
• Khawcharoenporn T, Apisarnthanarak A, Phetsuksiri B, et al. Tuberculin skin test and QuantiFERON-TB Gold In-tube Test for latent tuberculosis in Thai HIV-infected adults. Respirology. 2015;20:340–347.
   PubMed Web of Science ®Google Scholar
• Khongphatthanayothin M, Avihingsanon A, Teeratakulpisarn N, et al. Feasibility and efficacy of isoniazid prophylaxis for latent tuberculosis in HIV-infected clients patients in Thailand. AIDS Res Hum Retroviruses. 2012;28:270–275.
   PubMed Web of Science ®Google Scholar
• Oni T, Gideon HP, Bangani N, et al. Smoking, BCG and employment and the risk of tuberculosis infection in HIV-infected persons in South Africa. PLoS One. 2012;7:e47072.
   PubMedGoogle Scholar
• Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23:631–636.
   PubMed Web of Science ®Google Scholar
• Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384:682–690.
   PubMed Web of Science ®Google Scholar
• Pullar ND, Steinum H, Bruun JN, et al. HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study. BMC Infect Dis. 2014;14:667.
   PubMedGoogle Scholar
• Li J, Munsiff SS, Tarantino T, et al. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis. 2010;14:e292–e297.
   PubMed Web of Science ®Google Scholar
• Clark SA, Martin SL, Pozniak A, et al. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in HIV-1 patients with advanced disease. Clin Experi Immuno. 2007;150:238–244.
   PubMed Web of Science ®Google Scholar
• Lee LM, Lobato MN, Buskin SE, et al. Low adherence to guidelines for preventing TB among persons with newly diagnosed HIV infection, United States. Int J Tuberc Lung Dis. 2006;10:209–214.
   PubMed Web of Science ®Google Scholar
• Wyndham-Thomas C, Schepers K, Dirix V, et al. Implementation of latent tuberculosis screening in HIV care centres: evaluation in a low tuberculosis incidence setting. Epidemiol Infect. 2016;144:703–711.
   PubMed Web of Science ®Google Scholar
• Moolphate S, Lawpoolsri S, Pungrassami P, et al. Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. Glob J Health Sci. 2013;5:60–70.
   Google Scholar
• Saraceni V, Pacheco AG, Golub JE, et al. Physician adherence to guidelines for tuberculosis and HIV care in Rio de Janeiro, Brazil. Braz J Infect Dis. 2011;15:249–252.
   PubMed Web of Science ®Google Scholar
• Durovni B, Cavalcante SC, Saraceni V, et al. IDS. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS. 2010;24(Suppl 5):S49–S56.
   PubMedGoogle Scholar
• Szakacs TA, Wilson D, Cameron DW, et al. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect Dis. 2006 13;6:97.
   PubMed Web of Science ®Google Scholar